Welcome to the News Room

World’s first malaria vaccine works in major trial

Posted by:

Using IPRs effectively in neglected diseases R&D – What lessons can be learned from the positive results of the GSK and PATH’s Malaria Vaccine Initiative? Allowing partners which contribute proprietary technologies to maintain ownership and income from the end product may be key to achieving tangible results like those of the MVI. In this case, GSK, owner of many of the essential technologies of the vaccine, will supply the final product at a preferred price (cost+5%).This hybrid approach can support the certainty needed for pharmaceutical companies to partner for neglected disease R&D.


About the Author:

Prof. Meir Pugatch specialises in intellectual property policy, management and exploitation of knowledge assets, technology transfer, market access, pharmacoeconomics and political economy of public health systems. He has extensive experience in economic and statistical modelling and indexing; valuation of assets and design of licensing agreements; and providing strategic advice to international institutions, multinational corporations and SMEs from all sectors of the knowledge economy. Meir’s work is highly international and he has wide-ranging knowledge of North America, Europe, Asia and the Middle East.
  Related Posts
  • No related posts found.